JP2014530360A - 診断マーカーとしてのｏｘＭＩＦ - Google Patents

診断マーカーとしてのｏｘＭＩＦ Download PDF

Info

Publication number
JP2014530360A
JP2014530360A JP2014533883A JP2014533883A JP2014530360A JP 2014530360 A JP2014530360 A JP 2014530360A JP 2014533883 A JP2014533883 A JP 2014533883A JP 2014533883 A JP2014533883 A JP 2014533883A JP 2014530360 A JP2014530360 A JP 2014530360A
Authority
JP
Japan
Prior art keywords
mif
oxmif
antibody
disease
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014533883A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014530360A5 (enExample
Inventor
ミヒャエル・ティーレ
ランドルフ・イョット・ケルシュバオマー
ディルク・フェルケル
パトリス・ドゥイヤール
フリードリッヒ・シャイフリンガー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter Healthcare SA
Baxter International Inc
Original Assignee
Baxter Healthcare SA
Baxter International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare SA, Baxter International Inc filed Critical Baxter Healthcare SA
Publication of JP2014530360A publication Critical patent/JP2014530360A/ja
Publication of JP2014530360A5 publication Critical patent/JP2014530360A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
JP2014533883A 2011-10-07 2012-10-04 診断マーカーとしてのｏｘＭＩＦ Pending JP2014530360A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201161545042P 2011-10-07 2011-10-07
US61/545,042 2011-10-07
US201261624943P 2012-04-16 2012-04-16
US61/624,943 2012-04-16
US201261668841P 2012-07-06 2012-07-06
US61/668,841 2012-07-06

Publications (2)

Publication Number Publication Date
JP2014530360A true JP2014530360A (ja) 2014-11-17
JP2014530360A5 JP2014530360A5 (enExample) 2015-11-12

Family

ID=46980957

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014533883A Pending JP2014530360A (ja) 2011-10-07 2012-10-04 診断マーカーとしてのｏｘＭＩＦ

Country Status (8)

Country Link
US (1) US9958456B2 (enExample)
EP (1) EP2748613B1 (enExample)
JP (1) JP2014530360A (enExample)
AR (1) AR088244A1 (enExample)
AU (1) AU2012320597C1 (enExample)
HK (1) HK1198591A1 (enExample)
TW (1) TW201321408A (enExample)
WO (1) WO2013050453A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016175918A (ja) * 2012-04-16 2016-10-06 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 抗ｍｉｆ抗体と化学療法剤の併用療法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013050453A1 (en) 2011-10-07 2013-04-11 Baxter Healthcare S.A. Oxmif as a diagnostic marker
KR20150029017A (ko) * 2012-07-10 2015-03-17 박스터 헬쓰케어 에스에이 항-mif 면역조직화학
US9536304B2 (en) * 2013-08-30 2017-01-03 Dairy Quality Inc. Determining pathogens based on an image of somatic cells in a fluid sample
JP6615753B2 (ja) * 2013-10-04 2019-12-04 レジニアス リミテッド 細胞療法のためのバイオマーカー
AU2015206178A1 (en) * 2014-01-03 2016-07-07 Baxalta GmbH Anti-MIF immunohistochemistry
WO2016026956A1 (en) * 2014-08-22 2016-02-25 Baxalta GmbH Detection of cho-mif contaminations
JP2021526820A (ja) * 2018-06-07 2021-10-11 オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 癌治療のための抗ｏｘＭＩＦ／抗ＣＤ３抗体
CN115943160A (zh) * 2019-12-06 2023-04-07 翁科奥内研发有限责任公司 抗oxMIF/抗CD3双特异性抗体构建体
WO2022167474A1 (en) * 2021-02-03 2022-08-11 Oncoone Research & Development Gmbh ANTI-oxMIF RADIOIMMUNOCONJUGATE

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06217789A (ja) * 1984-05-24 1994-08-09 Ciba Geigy Ag ヒト−マクロファージ遊走阻止因子に対するモノクローナル抗体
WO2001064749A2 (en) * 2000-02-28 2001-09-07 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
JP2011510616A (ja) * 2008-01-04 2011-04-07 バクスター・インターナショナル・インコーポレイテッド 抗ｍｉｆ抗体

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4299814A (en) 1979-05-25 1981-11-10 Monsanto Company Radioimmunoassay of MIF
US4946674A (en) 1984-10-05 1990-08-07 Bioferon Biochemische Substanzen Gmbh & Co. Process for treatment of rheumatic diseases
US4708937A (en) 1984-10-15 1987-11-24 Brigham & Women's Hospital Purified migration inhibitory factor also having colony stimulating factor activity
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
DE3789413T2 (de) 1986-10-03 1994-07-28 Ciba Geigy Ag Lymphokin-ähnliche Peptide.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990011301A1 (en) 1989-03-17 1990-10-04 Genetics Institute, Inc. Human macrophage migration inhibitory factor
US5785054A (en) 1989-06-06 1998-07-28 Kelly; Patrick D. Genital lubricant with zinc salt, labelled as anti-viral agent
GB8915414D0 (en) 1989-07-05 1989-08-23 Ciba Geigy Novel cytokines
AU634314B2 (en) 1989-11-13 1993-02-18 Green Cross Corporation, The Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen
US5227459A (en) 1990-05-18 1993-07-13 Yale University Synthetic melanin
US5786168A (en) 1990-06-04 1998-07-28 Kirin Beer Kabushiki Kaisha Method for recombinant production of antigen non-specific glycosylation inhibiting factor (GIF)
US5585479A (en) 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
US6080407A (en) 1993-05-17 2000-06-27 The Picower Institute For Medical Research Diagnostic assays for MIF
US6774227B1 (en) 1993-05-17 2004-08-10 Cytokine Pharmasciences, Inc. Therapeutic uses of factors which inhibit or neutralize MIF activity
WO1994026307A1 (en) 1993-05-17 1994-11-24 The Picower Institute For Medical Research Inhibition of migration inhibitory factor in the treatment of diseases involving cytokine-mediated toxicity
US5559028A (en) 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
AU7394294A (en) 1994-05-16 1995-12-05 Human Genome Sciences, Inc. Macrophage migration inhibitory factor-3
US5747023A (en) 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
SI9400363A (en) 1994-09-19 1996-08-31 Mozetic Francky Bojana Human macrophage migration inhibitory factor of nonlymphoid origin, expression of mif in e. coli and purification of recombinant protein
AU4365796A (en) 1994-11-16 1996-06-06 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Methods for inhibiting cell proliferation by inhibiting the mitogenic activity of macrophage migration inhibitory factor
JPH0977799A (ja) 1995-09-13 1997-03-25 Sapporo Immuno Diagnostic Lab:Kk ヒト−マクロファージ遊走阻止因子（ヒト−ｍｉｆ）に対するモノクローナル抗体および該抗体を産生するハイブリドーマ
WO1997025344A1 (en) 1996-01-03 1997-07-17 The Australian National University Clip analogues and autoimmune disease
US6420188B1 (en) 1996-02-16 2002-07-16 The Picower Institute For Medical Research Screening assay for the identification of inhibitors for macrophage migration inhibitory factor
US6492428B1 (en) 2000-07-26 2002-12-10 The Picower Institute For Medical Research Compounds having MIF antagonist activity
US5726020A (en) 1996-06-11 1998-03-10 University Of Massachusetts Inhibition of II synthesis
US6297253B1 (en) 1996-10-15 2001-10-02 The Picower Institute For Medical Research Compounds and methods of use to treat infectious diseases
US6395276B1 (en) 1997-05-02 2002-05-28 Immunomedics, Inc. Immunotoxins directed against malignant cells
AU6336398A (en) 1997-02-24 1998-09-09 Johns Hopkins University, The Immunomodulatory polypeptides derived from the invariant chain of mhc class ii
CA2205680A1 (en) 1997-05-16 1998-11-16 The University Of Western Ontario Clip immunomodulatory peptide
US6011005A (en) 1997-09-18 2000-01-04 The Picower Institute For Medical Research Prevention of pregnancy miscarriages
AU747767B2 (en) 1997-11-05 2002-05-23 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
RU2236251C2 (ru) 1999-02-12 2004-09-20 Дзе Скриппс Рисерч Инститьют Способы лечения опухолей и метастазов с использованием комбинации антиангиогенной терапии и иммунотерапии
AU1235601A (en) 1999-10-29 2001-05-14 Cytokine Pharmasciences, Inc. Compounds having mif antagonist activity
US6268151B1 (en) 2000-01-20 2001-07-31 Isis Pharmaceuticals, Inc. Antisense modulation of macrophage migration inhibitory factor expression
CA2455915C (en) 2001-03-29 2013-05-14 Cytokine Pharmasciences, Inc. Methods and compositions for using mhc class ii invariant chain polypeptide as a receptor for macrophage migration inhibitory factor
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
US7205107B2 (en) 2001-12-21 2007-04-17 Cytokine Pharmasciences, Inc. Macrophage migration inhibitory factor (MIF) promoter polymorphism in inflammatory disease
US20050202010A1 (en) 2003-08-29 2005-09-15 Giroir Brett P. Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor
US8883160B2 (en) 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
CN105709237A (zh) 2005-12-16 2016-06-29 Ibc 医药公司 基于免疫球蛋白的多价生物活性装配体
CN100457895C (zh) 2006-05-24 2009-02-04 中国科学院生物物理研究所 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用
EP2079202A1 (en) * 2008-01-08 2009-07-15 NEC Corporation Method for optimizing the triggering of the transmission of buffer status reporting (BSR) information
JP5786204B2 (ja) 2010-01-19 2015-09-30 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． インスリン様増殖因子ｉ型受容体（ｉｇｆ−１ｒ）を標的とする新規クラスの単一特異性ヒト化抗体および二重特異性ヒト化抗体
AU2012327159B2 (en) 2011-10-07 2015-03-26 Baxalta GmbH Characterization of CHO-MIF gene and protein, and use thereof
WO2013050453A1 (en) 2011-10-07 2013-04-11 Baxter Healthcare S.A. Oxmif as a diagnostic marker

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06217789A (ja) * 1984-05-24 1994-08-09 Ciba Geigy Ag ヒト−マクロファージ遊走阻止因子に対するモノクローナル抗体
WO2001064749A2 (en) * 2000-02-28 2001-09-07 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
JP2011510616A (ja) * 2008-01-04 2011-04-07 バクスター・インターナショナル・インコーポレイテッド 抗ｍｉｆ抗体

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016175918A (ja) * 2012-04-16 2016-10-06 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ 抗ｍｉｆ抗体と化学療法剤の併用療法

Also Published As

Publication number Publication date
EP2748613A1 (en) 2014-07-02
AU2012320597A1 (en) 2013-05-09
EP2748613B1 (en) 2021-05-05
HK1198591A1 (en) 2015-04-30
AU2012320597C1 (en) 2015-10-15
AU2012320597B2 (en) 2015-05-21
US9958456B2 (en) 2018-05-01
US20140248638A1 (en) 2014-09-04
WO2013050453A4 (en) 2013-06-06
WO2013050453A1 (en) 2013-04-11
TW201321408A (zh) 2013-06-01
AR088244A1 (es) 2014-05-21

Similar Documents

Publication Publication Date Title
DK2231707T3 (en) Anti-mif antibodies
JP2014530360A (ja) 診断マーカーとしてのｏｘＭＩＦ
CN106574258B (zh) 抗-运甲状腺素蛋白人源化抗体
CN113226471A (zh) Il-11ra抗体
WO2015115332A1 (ja) 抗トランスサイレチンヒト抗体
RU2749591C1 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АНТИТЕЛО, СПЕЦИФИЧНО СВЯЗЫВАЮЩЕЕСЯ С N-КОНЦОМ ЛИЗИЛ-тРНК-СИНТЕТАЗЫ, В КАЧЕСТВЕ ЭФФЕКТИВНОГО ИНГРЕДИЕНТА ДЛЯ ПРОФИЛАКТИКИ ИЛИ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ, ОБУСЛОВЛЕННОГО МИГРАЦИЕЙ КЛЕТОК
US20150355199A1 (en) Agents, kits and methods for complement factor h-related protein 1 detection
JP2015523572A (ja) 抗ｍｉｆ免疫組織化学法
CN110760483B (zh) 具牛、羊交叉反应的抗TNF-α单克隆抗体的制备及应用
TW201605886A (zh) 作爲治療標靶的ｍｉｆ
JP2016502669A (ja) 抗ｍｉｆ抗体細胞遊走アッセイ
HK1181052A (en) Anti mif antibodies
HK1147762B (en) Anti mif antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150916

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150916

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160511

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160608

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20160615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161031

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170110

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170316

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171010